Breaking News Instant updates and real-time market news.

MRK

Merck

$62.30

0.43 (0.70%)

07:06
11/22/16
11/22
07:06
11/22/16
07:06

Merck announces new data presentation regarding Keytruda investigational use

Merck announced that new data regarding the investigational use of KEYTRUDA, the company's anti-PD-1 therapy, in patients with a range of blood cancers including classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma, will be presented at the 58th Annual Meeting of the American Society of Hematology in San Diego, December 3-6. The KEYTRUDA clinical development program includes more than 30 tumor types in more than 360 clinical trials, including over 200 trials that combine KEYTRUDA with other cancer treatments. For hematologic malignancies specifically, Merck is conducting broad immuno-oncology research assessing the role of monotherapy and combination regimens with KEYTRUDA. The program includes nearly 40 ongoing studies - several of which are registration-enabling trials - across more than 20 hematologic disease subtypes, including leukemia, lymphomas, and myeloma.

MRK Merck
$62.30

0.43 (0.70%)

10/13/16
10/13/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Merck (MRK) upgraded to Buy from Neutral at BofA/Merrill with analyst Colin Bristow citing its opportunity in first line lung cancer. 2. Viacom (VIA, VIAB) upgraded to Market Perform from Underperform at Wells Fargo and to Buy from Underperform at BofA/Merrill. 3. TD Ameritrade (AMTD) and Charles Schwab (SCHW) were upgraded to Buy from Neutral at BofA/Merrill. 4. Talend (TLND) upgraded to Buy from Neutral at Goldman with analyst Jesse Hulsing saying the company will benefit from analytic workloads moving to the cloud. 5. CSC (CSC) upgraded to Buy from Neutral at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/19/16
LEER
10/19/16
NO CHANGE
LEER
Roche Tecentriq approval increases competition, says Leerink
Leerink analyst Seamus Fernandez says that the FDA approval of Roche's (RHHBY) Tecentriq in second-line non-small cell lung cancer patients regardless of PD-L1 expression comes as no surprise given its previously reported overall survival advantage. Nonetheless, the analyst believes it creates new competition for Bristol-Myers' (BMY) Opdivo and Merck's (MRK) Keytruda in this setting.
10/24/16
RHCO
10/24/16
NO CHANGE
RHCO
Merck Keytruda to have several positive catalysts, says SunTrust
SunTrust analyst John Boris says that several trials of Merck's Keytruda will be stopped early "across multiple tumor types," providing a positive catalyst. Boris says that Keytruda should be approved for 1LNSCLC on or before December 24 and KN-21 chemo combo compendium listing in 1H17. He keeps a $73 price target and Buy rating on Merck.
10/25/16
RHCO
10/25/16
NO CHANGE
RHCO
Merck shares should be bought after early FDA approval, says SunTrust
After Merck announced that the FDA had approved the company's Keytruda treatment for the first-line metastatic non-small cell lung cancer with tumor proportion scores of 50% or higher, SunTrust analyst John Boris says that such patients represent about 30% "of the prevalent first-line population." He adds that the approval was earlier than expected and gives Keytruda an approximately 15 month lead over competing drugs in NSCLC. The analyst thinks that the early approval will enable the company's 2021 revenue to beat expectations by a significant amount, and he recommends buying the stock on the news.

TODAY'S FREE FLY STORIES

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

05:49
09/25/17
09/25
05:49
09/25/17
05:49
Hot Stocks
Amazon Web Services announces opening of data centers in Middle East by 2019 »

Amazon Web Services, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

CVE

Cenovus Energy

$10.28

0.18 (1.78%)

05:46
09/25/17
09/25
05:46
09/25/17
05:46
Hot Stocks
Cenovus Energy reaches agreement to sell Suffield assets for $512M »

Cenovus Energy has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JHG

Janus Henderson Group

$33.96

0.42 (1.25%)

05:39
09/25/17
09/25
05:39
09/25/17
05:39
Initiation
Janus Henderson Group initiated  »

Janus Henderson Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EMES

Emerge Energy

$9.17

0.44 (5.04%)

05:36
09/25/17
09/25
05:36
09/25/17
05:36
Initiation
Emerge Energy initiated  »

Emerge Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCLP

Hi-Crush Partners

$10.10

0.3 (3.06%)

05:34
09/25/17
09/25
05:34
09/25/17
05:34
Initiation
Hi-Crush Partners initiated  »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

EXEL

Exelixis

$24.47

-3.54 (-12.64%)

, DSNKY

Daiichi Sankyo

$23.03

0.17 (0.74%)

05:34
09/25/17
09/25
05:34
09/25/17
05:34
Hot Stocks
Exelixis: ESAX-HTN pivotal study in essential hypertension met primary objective »

Exelixis (EXEL) announced…

EXEL

Exelixis

$24.47

-3.54 (-12.64%)

DSNKY

Daiichi Sankyo

$23.03

0.17 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

VFC

VF Corp.

$62.20

0.35 (0.57%)

, UAA

Under Armour

$16.41

-0.08 (-0.49%)

05:31
09/25/17
09/25
05:31
09/25/17
05:31
Downgrade
VF Corp., Under Armour, Under Armour rating change  »

VF Corp. downgraded to…

VFC

VF Corp.

$62.20

0.35 (0.57%)

UAA

Under Armour

$16.41

-0.08 (-0.49%)

UA

Under Armour

$15.04

-0.09 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

UAA

Under Armour

$16.41

-0.08 (-0.49%)

, UA

Under Armour

$15.04

-0.09 (-0.59%)

05:28
09/25/17
09/25
05:28
09/25/17
05:28
Upgrade
Under Armour, Under Armour, VF Corp. rating change  »

Under Armour upgraded to…

UAA

Under Armour

$16.41

-0.08 (-0.49%)

UA

Under Armour

$15.04

-0.09 (-0.59%)

VFC

VF Corp.

$62.20

0.35 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

SNAP

Snap

$13.70

-0.07 (-0.51%)

05:24
09/25/17
09/25
05:24
09/25/17
05:24
Recommendations
Snap analyst commentary  »

Snap price target lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMP

Compass Minerals

$60.10

-9.4 (-13.53%)

05:20
09/25/17
09/25
05:20
09/25/17
05:20
Upgrade
Compass Minerals rating change  »

Compass Minerals upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Sep

  • 29

    Sep

COR

CoreSite Realty

$108.49

-1.86 (-1.69%)

05:18
09/25/17
09/25
05:18
09/25/17
05:18
Initiation
CoreSite Realty initiated  »

CoreSite Realty initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

ROST

Ross Stores

$60.89

-0.02 (-0.03%)

05:17
09/25/17
09/25
05:17
09/25/17
05:17
Upgrade
Ross Stores rating change  »

Ross Stores upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OFC

Corporate Office Properties

$32.53

-0.13 (-0.40%)

05:11
09/25/17
09/25
05:11
09/25/17
05:11
Upgrade
Corporate Office Properties rating change  »

Corporate Office…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABMRF

ABN Amro

05:08
09/25/17
09/25
05:08
09/25/17
05:08
Upgrade
ABN Amro rating change  »

ABN Amro upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$39.42

0.32 (0.82%)

05:05
09/25/17
09/25
05:05
09/25/17
05:05
Upgrade
General Motors rating change  »

General Motors upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGLOY

Anglo American

$9.12

-0.1 (-1.08%)

04:59
09/25/17
09/25
04:59
09/25/17
04:59
Downgrade
Anglo American rating change  »

Anglo American downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTB

Butterfield

$36.57

0.45 (1.25%)

04:56
09/25/17
09/25
04:56
09/25/17
04:56
Downgrade
Butterfield rating change  »

Butterfield downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSAR

Versartis

$2.68

-18.925 (-87.62%)

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Downgrade
Versartis rating change  »

Versartis downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Conference/Events
Cowen retail analyst hold an analyst/industry conference call »

Retailing/Specialty…

HSC

Harsco

$19.75

0.35 (1.80%)

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Conference/Events
Harsco management to meet with Lake Street »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

IIVI

II-VI

$40.40

0.45 (1.13%)

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Conference/Events
II-VI management to meet with B. Riley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 28

    Sep

  • 13

    Nov

AMCX

AMC Networks

$59.08

0.14 (0.24%)

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Conference/Events
AMC Networks management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

04:55
09/25/17
09/25
04:55
09/25/17
04:55
General news
Dallas Fed Mfg Survey General Activity Index to be reported at 10:30 »

September Dallas Fed Mfg…

04:55
09/25/17
09/25
04:55
09/25/17
04:55
General news
Chicago Fed National Activity Index Level to be reported at 08:30 »

August Chicago Fed…

HES

Hess Corp.

$44.50

0.87 (1.99%)

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Conference/Events
Hess Corp. management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.